Long‐term plasma monitoring of THC and CBD in pediatric drug‐resistant epilepsy: Implications for cannabidiol therapy with Epidyolex®
Epilepsia Open · 2025
DOI: 10.1002/epi4.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von Alessia Cafaro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina, Gaslini, Genoa, Italy. Hauptthemen laut MEDLINE: Cannabidiol, Drug Resistant Epilepsy, Dronabinol, Anticonvulsants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study evaluated long‐term plasma concentrations of cannabidiol (CBD) and Δ9‐tetrahydrocannabinol (THC) in children receiving highly purified cannabidiol (hpCBD; Epidyolex®) therapy for drug‐resistant epilepsy. A retrospective analysis was performed on 38 patients with a median age of 11 years (IQR, 5) treated in a single center from 2019 to 2024. Incremental doses of Epidyolex® (mean dose: 13.6 mg/kg/day) were administered, and plasma levels of CBD and THC were measured using liquid chromatography–tandem mass spectrometry (LC–MS/MS). THC remained consistently undetectable (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina, Gaslini, Genoa, Italy.
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
- Paediatric Neurology and Muscular Disease Unit, IRCCS Istituto Giannina Gaslini, full member of ERN EpiCARE, Genoa, Italy.
- Unit of Child Neuropsychiatry, IRCCS Gaslini, Genoa, Italy.
- National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
- Department of Excellence-Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy.
ORCID-Profile: Alessia Cafaro, Federica Pigliasco, Sebastiano Barco, Maria Margherita Mancardi, Pasquale Striano
Zitieren
APA
Cafaro, A., Riva, A., Pigliasco, F., Barco, S., Manca, V., Stella Vari, M., Mancardi, M. M., Nobili, L., Pichini, S., Busardò, F. P., Striano, P., & Cangemi, G. (2025). Long‐term plasma monitoring of THC and CBD in pediatric drug‐resistant epilepsy: Implications for cannabidiol therapy with Epidyolex®. Epilepsia Open. https://doi.org/10.1002/epi4.70112
Vancouver
Cafaro A, Riva A, Pigliasco F, Barco S, Manca V, Stella Vari M, et al. Long‐term plasma monitoring of THC and CBD in pediatric drug‐resistant epilepsy: Implications for cannabidiol therapy with Epidyolex®. Epilepsia Open. 2025. doi:10.1002/epi4.70112
BibTeX
@article{Cafaro2025,
author = {Cafaro, Alessia and Riva, Antonella and Pigliasco, Federica and Barco, Sebastiano and Manca, Valentina and Stella Vari, Maria and Mancardi, Maria Margherita and Nobili, Lino and Pichini, Simona and Busardò, Francesco Paolo and Striano, Pasquale and Cangemi, Giuliana},
title = {Long‐term plasma monitoring of THC and CBD in pediatric drug‐resistant epilepsy: Implications for cannabidiol therapy with Epidyolex®},
journal = {Epilepsia Open},
year = {2025},
doi = {10.1002/epi4.70112}
}
EUVIMED